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Abstract
During the neonatal period, the
diagnosis of an error of metabolism
(EM) was once thought to portend a
poor prognosis or lethality. Over the
past two decades, the prognosis of
many EMs has changed. The critical
aspect of the metabolic evaluation in a
sick newborn is to rapidly identify
whether there may be a metabolic
problem. If there is a metabolic
problem, the goal is to minimize the
sequelae of the specific disorder. This
review will explore how to approach
and evaluate a newborn suspected of
having an EM. A discussion of clinical
and laboratory findings that often
accompany EM will be included.
Not So Rare:
Errors of
Metabolism
During the
Neonatal Period
By Sandra A. Banta-Wright, MN, RNC, NNP, and
Robert D. Steiner, MD
At delivery, a full-term newborn may appear active and healthy. How-ever, over a course of hours, days, or weeks, nonspecific signs andsymptoms of distress may develop. In some cases, there will be a
gradual decline in the infant’s condition with slow deterioration. Alternatively,
the onset of distress can be sudden, catastrophic, and life threatening. The
symptoms usually indicate a differential diagnosis of respiratory, cardiac,
gastrointestinal, neurological, and infectious disease. There is a tendency to not
include consideration of an error of metabolism (EM), formerly referred to as
an inborn error of metabolism, until the above “more common causes of
distress” have been excluded–this approach can be fatal. During the first year of
life, EMs mimic or even predispose to these conditions. Individual EMs are, for
the most part, indeed rare. Collectively, however, EM disorders are not an
infrequent cause of distress in the neonatal period. It is now estimated that 1 in
1,000 newborns is at risk for being affected by an EM.1 Due to the large
numbers of EM that can present during the neonatal period, some fear that, to
appropriately diagnosis EM, the clinician must understand numerous biochem-
ical pathways and their interrelationships. Fortunately, approaching a suspi-
cious illness in a newborn based on even a limited knowledge of biochemistry
and metabolic laboratory studies can lead to effective diagnostic testing and
management. The recognition of a neonate with EM can be accomplished using
an organized and rational approach based on diagnostic algorithms presented in
this review. When a newborn presents acutely with signs of an EM, appropriate
therapy needs to be initiated rapidly due to the high risk of morbidity and
mortality. Thus, EM must be considered concurrently in the differential diag-
nosis that includes the more common disease processes. Increasingly, disorders
of metabolism are being managed successfully with acceptable outcomes.
Appropriate therapy, in many cases, can result in prevention of mental retar-
dation and death.
It is the purpose of this review to provide an outline for an approach to the
evaluation of a newborn suspected of having an EM. In addition, the major
clinical and laboratory findings of EMs presenting during the neonatal period
will be reviewed. A limited discussion of treatment will focus on the stabili-
zation and acute management of newborns with EM. The discussion will be
limited to those EM that present during this early period of life, rather than later
during infancy, childhood, or adulthood. Detailed bio-
chemical pathways of EMs are not provided. More com-
prehensive discussions of each of these topics can be
found in recent editions of reference textbooks.2-4
Errors of Metabolism during the Neonatal Period
There are over 300 EM that have been identified inman.4 The disorders of metabolism diagnosed during
the newborn/infancy period can be categorized, for the
most part, into 1 of 6 areas. These are disorders of: 1)
amino acids, 2) carbohydrates, 3) fatty acid oxidation, 4)
lysosomal and peroxisomal function, 5) mitochondrial en-
ergy metabolism, and 6) organic acids. A summary of EM
that have been diagnosed during the neonatal period is
listed in Table 1. This summary should not be considered
all inclusive. New disorders of EM continue to be eluci-
dated with the advances in clinical research.
Clinical Presentation of EM in the Neonate
As previously discussed, the clinical manifestations ofEM are similar to the presentation of several other
newborn disorders. Newborns have only a few ways to
respond to an acute insult, such as an EM.5,6 These re-
sponses include signs and symptoms of respiratory, car-
diac, gastrointestinal, and neurological distress. These
symptoms are summarized in Table 2.
Laboratory Evalualtion of EM in a neonate
The laboratory evaluation for a newborn suspected ofhaving an EM can be illustrated as a pyramid in Fig
1. The specific details of collection, handling, processing,
and shipping, if needed, of laboratory samples must be
clearly understood before the samples are obtained. In
addition, during this time period, frequent communication
and collaboration with laboratory personnel in more than
one laboratory may be needed. This will expedite testing
and avoid needless delay and repetition of sample collec-
tion and processing from an already compromised new-
born. The first tier includes broadly focused screening tests
that can provide a relatively rapid and inexpensive diag-
nostic evaluation. Several of these tests are routinely per-
formed during the care of a sick newborn. A significant
imbalance may be identified, which when promptly treated
may prevent long-term sequelae. Additional tests for met-
abolic disease are listed in tier 2. Tier 2 tests of the
pyramid provide more information as to differential diag-
nosis. The studies in tier 1 and 2, when combined, can help
direct care of the patient and the need for consultation with
a regional medical center where clinical biochemical ge-
netics/metabolic disease expertise is available. Tier 3 of
the pyramid focuses on the metabolic disease process and
provides information for consultation with the metabolic
disease specialist. These tests are not routinely available in
many local hospital laboratories. As these studies require
highly specialized laboratory skills and equipment, these
tests are generally available at larger, regional medical
centers. In addition, some commercial laboratories also
offer these tests. Many of the commercial laboratories,
with some notable exceptions, cannot provide STAT anal-
yses and/or expert result interpretation. It can be difficult
to interpret results of laboratory tests performed at com-
mercial laboratories where the techniques used can be
different from academic laboratories, though recently the
quality of testing offered by several commercial laborato-
ries has improved greatly. The fourth tier of the pyramid
involves highly specialized tests in the diagnosis of EM.
Definitive diagnostic testing can require specific enzy-
matic analysis using white blood cells, cultured skin fi-
broblasts, or other tissue specimen, such as muscle. Only
a few laboratories perform many of the enzyme and mu-
tation analyses that are required for confirmation of the
diagnosis. The results may not be available immediately,
but can take days, weeks, or months to be reported by the
specific biochemical genetic laboratory. The metabolic
disease consultants can assist in identifying which specific
tests to order, the priority of the tests, and can provide
direction in the initial treatment of the neonate.
Tandem Mass Spectrometry
With increasing use of tandem mass spectrometry(MS/MS), the analysis of acylcarnitines and amino
acids in dried filter paper blood spot (Guthrie) specimens
has proven useful as a method for mass newborn screening
for a number of amino acid, fatty acid oxidation, organic
acid, and urea cycle disorders.7 This technique has been
referred to as expanded newborn screening. The analysis
usually requires only one or two dried filter paper blood
spots. In addition, it is automated and usually takes only 1
to 2 minutes per sample. When a newborn is suspected of
having an EM, the regional academic or state laboratory
should be notified to facilitate a more rapid screening
result. However, the result is dependent on the sample
being in the laboratory and acceptable quality of the blood
spot. The ability to use MS/MS to provide direction to-
ward the differential diagnosis and the collection of con-
firmatory laboratory tests for many metabolic disorders
has been life saving for many newborns. However, not
every state or region has MS/MS available for expanded
newborn screening. In addition, the test is not 100% sen-
Table 1. Summary of Errors of Metabolism that May Present in the Neonatal Period
Amino Acids Carbohydrate Fatty Acid Oxidation
Lysosomal and
Peroxisomal Function
Mitochondrial
Energy
Metabolism Organic Acids
Argininemia Galactosemia,
Classical
Carnitine/acylcarnitine
translocase
deficiency (CACT)
Farber disease
Fucosidosis
Hypertrophic
cardiomyopathy
and myopathy
(infantile onset)
2-Methylbutryrl-CoA
dehydrogenase
deficiency (2MBCD
or SBCAD)
Argininosuccinic aciduria
(ASA lyase deficiency)
Hereditary fructose
intolerance
Carnitine palmitoyl
transferease
deficiency type I
(CPT-I)
Gaucher disease,
infantile form
Carbamyl phosphate
synthetase deficiency
(CPS)
Fructose-1,6-
diphosphatase
deficiency
Glycogen storage
disease, type II
(Pompe disease)
Lethal infantile
cardiomyopathy
(LIC)
Citrullinemia (ASA
synthetase deficiency)
Glycogen storage
disease, type I
Carnitine palmitoyl
transferase
deficiency type II
(CPT-II)
GM1 gangliosidosis Lethal infantile
cardiomyopathy
2-Methyl-3OH butyric
aciduria
Homocystinuria (HCU) Glycogen storage
disease, type III
Carnitine transport
defect
I-cell disease X-linked
cardioskeletal
myopathy
(Barth
syndrome)
3-Methylcrotomyl-
CoA carboxylase
deficiency (3MCC)
Hyperornithinemia–
hyperammonemia–
homocitrullinuria
(HHH) Syndrome
Other glycogen
storage diseases
Glutaric aciduria, type
I (GA-I)
Mucopolysaccharidosis
type VII
Hyperphenylalaninemias
(PKU, HPhe)
Classical PKU,
Hyperphenylalaninemia,
Biopterin Cofactor
Defects
Pyruvate carboxylase
deficiency (PCD)
Long chain 3-
hydroxyacyl-CoA
dehydrogenase
deficiency
(LCHADD)
Neonatal
adrenoleukodystrophy
Lethal infantile
mitochondrial
disease (LIMD)
Pearson
syndrome
3-Methylgluta
conyl-CoA
hydratase deficiency
Phosphoenolpyruvate
carboxykinase
deficiency
(PEPCK)
Trifunctional protein
deficiency
Medium chain acyl-
CoA dehydrogenase
(MCADD)
Niemann–Pick disease
type A, C/Sialidosis,
type II/Wolman
disease/Zellweger
syndrome
Progressive
infantile
poliodystrophy
(Alpers
Disease)
3-hydroxy-3-
methylglutaryl-CoA
lyase deficiency
(HMG, coAlyase)
Lysinuric protein intolerance
(LPI)
Multiple acyl-CoA
dehydrogenase
deficiency (MADD
or GAII, Glutaric
acidemic, type II)
Pyruvate
dehydrogenase
deficiency
(Leigh
syndrome)
Adenosylcobalamin
synthesis defects/
Biotinididase
deficiency
Maple syrup disease (MSD)
Nonketotic Hyperglycinema
(NKG)
Isovaleric acidemia
(IVA)
Ornithine transcarbamylase
deficiency (OTC)
Very long chain acyl-
CoA dehydrogenase
deficiency
(VLCADD)
Methylmalonic
acidemias (MMA)
Pyroglutamic Aciduria/5-
oxoprolinuria
Mitchondrial
acetoacetyl-CoA
thiolase deficiency
(BKT, 3-deficiency)
Sulfite oxidase
Deficiency/Molybdenum
Cofactor deficiency
Tyrosinemia
Transient neonatal, type I,
type II, type III
Multiple carboxylase
deficiency (MCD)
Propionic acidemia
(PA)
sitive for some disorders. The result may be available in
some cases only after the neonate has already presented
clinically and is in the neonatal intensive care unit in
critical condition.
Differential Diagnosis of EM
The acute onset of EM in the neonate can be dividedinto two main categories of presentation: metabolic
acidosis and hyperammonemia. A third category of pre-
sentation is hypoglycemia, but this is not as common as
metabolic acidosis and hyperammonemia. For discussion
of hypoglycemia and EM, several reviews are available.3-5
An approach to the differential diagnosis with each of
these clinical findings will be presented. The algorithms
direct an approach to care that must be individualized to
meet the newborn’s specific needs. It is important to
remember that EM can present with catastrophic illness in
the neonatal period with no acidosis and a normal ammo-
nia level. Examples include nonketotic hyperglycinemia
(NKH), Zellweger syndrome, Cobalamin C defects, and
pyridoxine dependency.8-12
Metabolic Acidosis
Metabolic acidosis is defined as a low pH (7.35)due to an excess of acid (H) or a deficit of base
(HCO3). This occurs when there is an increased produc-
tion of fixed or nonvolatile acids with a simultaneous
decrease in the buffering capacity. The anion gap should
be calculated to elucidate whether the metabolic acidosis
is caused by an accumulation of organic acids or a de-
crease in bicarbonate. This is important in establishing the
diagnosis of suspected EM. The anion gap is calculated by
Sodium – (Chloride  Bicarbonate).13 Hyperchloremic
acidosis is a hallmark of metabolic acidosis due to bicar-
bonate wasting and usually occurs in newborns with in-
testinal or renal disorders. When the anion gap is increased
(16) with a normal chloride level, the acidosis is from
excess acid production.
Metabolic acidosis is a common finding in the sick
newborn. In some cases, the metabolic acidosis is acute,
severe, and life threatening, as in shock. In other cases, the
acidosis is mild, but persistent and, in still others, may be
intermittent. The most common approach to metabolic
acidosis in neonates is to correct the acidosis by adminis-
tering bicarbonate. Metabolic acidosis caused by EM pre-
senting acutely in the neonatal period, almost without
exception, will not respond to bicarbonate, except tran-
siently. The effective treatment of acidosis in EM is cor-
rection of the cause of the acidosis, such as decreasing the
endogenous overproduction of specific acids.
Several categories of EM may present with metabolic
acidosis and an increased anion gap (Table 3). A simpli-
fied flowchart for the evaluation of a newborn with met-
abolic acidosis and an increased anion gap is presented in
Fig 2. The largest group associated with metabolic acido-
sis during the neonatal period is organic acidemias.14 In
addition, this situation occurs also with some amino acid
disorders. Other disorders, such as defects in pyruvate
metabolism or in the respiratory chain, may present with
metabolic acidosis and an elevated lactate during the neo-
natal period, but these may not always have an increased
anion gap.15 However, these newborns will often not have
specific diagnostic elevations of organic acids on urine
organic acid analysis. A lactate/pyruvate ratio less than 25
suggests pyruvate dehydrogenase deficiency (PDH) or
other disorders of pyruvate metabolism, whereas a ratio
greater than 25 suggests a respiratory chain defect.16-20 In
addition, fatty acid oxidation disorders, such as medium-
chain acyl-CoA dehydrogenase deficiency (MCADD),
may present with metabolic acidosis and hypoglycemia.21
The organic acidemias, such as methylmalonic aci-
demia (MMA), propionic acidemia (PPA), and isovaleric
acidemia (IVA), form the most common category to be
considered in the evaluation of metabolic acidosis.22-25 All
three disorders are the result of defects in branched chain
amino acid metabolism, affecting the catabolism of iso-
leucine (ILE), leucine (LEU), and valine (VAL). All dis-
orders are autosomal recessive. These three disorders are
almost clinically indistinguishable from one another when
they present in the neonatal period. The clinical finding is
Table 2. Common Clinical Manifestations of Errors of
Metabolism Presenting in the Newborn/Infancy Period
Gastrointestinal Signs
Cholestasis
Diarrhea
Jaundice
Poor feeding
Vomiting
Neurological Signs
Abnormalities of tone
Irritability
Lethargy (progressing toward coma)
Poor/weak suck
Seizures
Organomegaly
Heart
Liver
Spleen
Respiratory Signs
Apnea
Respiratory failure
Tachypnea/hyperpnea
Fig 1. Pyramid of laboratory tests for suspected metabolic disease in a newborn.
a healthy newborn at birth who becomes rapidly ill after
the first day of life. Clinical signs include ketoacidosis,
poor feeding, vomiting, dehydration, hypotonia, lethargy,
tachypnea/hyperpea, seizures, coma, and an unusual odor
(Table 4). The main laboratory diagnostic tool is urinary
organic acid analysis. The urine organic acid analysis will
reveal the specific elevated urinary organic acids.26 In
addition, ketonuria will be present. When associated with
metabolic acidosis, particularly in the neonatal period,
ketonuria is almost always pathognomic of an error of
metabolism. The plasma lactate is often elevated in or-
ganic acidemias as a result of secondary interference with
coenzyme A (CoA) metabolism. Notably, neutropenia and
thrombocytopenia are common and mimic neonatal sepsis.
Hyperammonemia is common, but is not usually as im-
pressive in organic acid disorders as in urea cycle defects.
There will be an increased acylcarnitine-to-free carnitine
ratio, which is accompanied by abnormal patterns of blood
acylcarnitines.27,28
The management of a newborn with a presumed diag-
nosis of an organic acidemia is to first stabilize the new-
born. Within 24 to 48 hours, the results of quantitative
amino acid and organic acid analysis should be available.
If the laboratory cannot provide results in this time frame,
alternative arrangements with another laboratory should
be pursued. Treatment at this time is directed toward the
removal of the accumulating metabolites, such as ammo-
nia or organic acid intermediates, with hemodialysis.29 If a
center is unable to provide hemodialysis to a newborn,
transfer should be strongly considered. Exchange transfu-
sions, peritoneal dialysis, or hemofiltration are less effi-
cient than hemodialysis in managing these disorders.30
Insulin can be used to augment the anabolic state.31 Car-
nitine is used to remove toxic metabolites during the acute
phase.32-34 During an acute illness, intravenous carnitine is
preferred either as a continuous drip or in six divided daily
doses over oral administration. After the newborn has been
stabilized, oral feedings should be reinitiated. A wide
range of specialty formulas are available that restrict cer-
tain amino acids.35 The assistance of a dietitian with
experience in managing EM and the metabolic specialist is
vital. Efforts to reduce the endogenous production of toxic
metabolites may include antibiotic suppression of gut flora
that produce metabolites that enter the newborn’s blood-
stream, such as the long-term use of metronidazole in the
treatment of methylmalonic and propionic acidemias.36 In
addition, specific vitamins, such as hydroxocobalamin,
may be provided as cofactors for certain enzyme deficien-
cies. Several abnormalities in the reduction of cobalamin
result in impaired methylmalonly-CoA mutase (MMM)
activity in MMA. Some newborns with decreased MMM
activity will respond to pharmacologic doses of hydroxo-
cobalamin with enhancement of enzyme activity and in-
creased tolerance of ILE, methionine (MET), threonine
(THR), and VAL.37,38 The success in the acute manage-
ment of the organic acidemias has led to improved sur-
vival and outcome. The long-term prognosis varies widely
for different disorders and within disorders due to the
genetic heterogeneity.
Hyperammonemia
In the newborn period, a normal ammonia level is lessthan 50 mol/L.39 A blood ammonia level between
70 and 100 mol/L should be viewed in conjunction
with clinical findings. An elevated ammonia level  100
mol/L indicates an abnormality in nitrogen balance. A
typical clinical presentation of neonatal hyperammonemia
is a full-term newborn who is initially well the first day of
life. After 24 hours, the newborn becomes a poor feeder,
lethargic with hypotonia, vomits frequently, and is hyper-
pneic.40 Hyperammonemia is a life-threatening condition,
as elevated ammonia is a toxin especially on the central
nervous system. If not identified and treated rapidly, the
newborn will have irreversible neurological sequelae.
There are several disorders that can cause hyperam-
monemia in the neonatal period (Table 5). When hyper-
ammonemia is present in the newborn/infancy period, an
attempt to identify a diagnosis is essential. A systematic
Table 3. Errors of Metabolism with Metabolic Acidosis and
Increased Anion Gap in Neonates
Amino acids
Maple Syrup Disease (MSD)
Carbohydrate disorders
Fructose-1,6-diphosphatase deficiency
Fatty acid oxidation
Carnitine/acylcarnitine translocase deficiency (CACT)
Carnitine palmitoyl transferase deficiency, type II (CPT-II)
Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency
(LCHADD)
Medium chain acyl-CoA dehydrogenase deficiency
(MCADD)
Trifunctional protein deficiency
Very long chain acyl-CoA dehydrogenase deficiency
(VLCADD)
Organic acidemias
2-Methyl-3-OH butyric aciduria
3-Hydroxy-3-methylglutaryl-CoA (HMG) lyase deficiency
3-Methylcrotonyl CoA carboxylase deficiency (3MCC)
Isovaleric academia (IVA)
Methylmalonic acidemias (MMA)
Multiple carboxylase deficiency (MCD)
Propionic acidemia (PA)
Pyroglutamic aciduria
approach for the differential diagnosis of hyperammone-
mia is presented in Fig 3. It is very important to remember
that the first step in evaluating suspected hyperammone-
mia is to obtain an accurate blood ammonia level.41 The
venous ammonia sample must be collected, stored, and
transported on ice to the laboratory. Once in the labora-
tory, this specimen must be rapidly analyzed and not run
as a routine and must be reported with an adjustment for
the newborn age.
Newborns that present with hyperammonemia during
the first day of life usually are either premature or full-
term newborns with a secondary hyperammonemia, such
as a pyruvate carboxylase deficiency (PCD).42,43 The se-
verely elevated ammonia level associated with prematurity
is known as transient hyperammonemia of the newborn
(THAN).42 THAN typically presents in a preterm infant of
approximately 36 weeks’ gestation, who has respiratory
distress and significant hyperammonemia. Survivors of
THAN do not experience recurrent episodes of hyperam-
monemia. The neurological outcome of THAN is depen-
dent on the extent of the neonatal insult. As a result, this
disorder should not be ignored, rather rapid and vigorous
medical intervention is required. The authors have had
experience with premature infants with ammonia levels
greater than 2,000 mol/L and normal outcome in THAN.
Hyperammonemia after the first 24 hours following
birth is more characteristic of a primary hyperammonemia,
which includes mainly urea cycle defects.44 Other catego-
ries of EM that also present after 24 hours of age with
hyperammonemia include organic acidemias and fatty
acid oxidation disorders.45 The key to differentiation is the
presence or absence of acidosis, ketosis, or hypoglyce-
mia.46 The urea cycle defects usually present with respi-
ratory alkalosis due to the hyperpnea, induced by the
hyperammonemia. In contrast, the initial presentation of
many organic acidemias is severe metabolic acidosis with
an increased ion gap. Also, fatty acid oxidation disorders
tend to present with mild metabolic acidosis. The second
Fig 2. Simplified flowchart of the evaluation of a newborn with metabolic acidosis and an increased anion gap. HMG, 3-hydroxy-3-
methylglutaryl-CoA lyase deficiency; IVA, isovaleric acidemia; LCHADD, long chain 3-chydroxyacyl-CoA dehydrogenase defi-
ciency; MSD, Maple syrup disease; MCADD, medium chain acyl-CoA dehydrogenase deficiency; MMA, methylmalonic acidemia;
MADD, multiple acyl-CoA dehydrogenased deficiency (GAII, glutaric acidemia, type II); PEPCK, phosphoenolpyruvate carbosykinase
deficiency; PPA, propionic acidemia; PCD, pyruvate carboxylase deficiency; VLCADD, very long chain acyl-CoA dehydrogenase
deficiency. Adapted with permission from Ward JC. Inborn errors of metabolism of acute onset in infancy. Pediatr Rev 11:205-216,
1990.
distinguishing feature of the urea cycle defects is the
absence of ketosis, which is easily determined by a urine
dipstick to check for the presence of ketones.44 The last
variable is the absence or presence of hypoglycemia. The
classical presentation of fatty acid oxidation disorders is
nonketotic hypoglycemia or hypoketotic hypoglycemia.47
Lastly, ketotic hypoglycemia with acidosis is characteris-
tic of PCD in addition to organic acidemias.48
The largest category of disorders with hyperammone-
mia is urea cycle defects.43 In the absence of acidosis,
ketosis, and hypoglycemia, a tentative diagnosis of urea
cycle defect should be considered. Disorders to be in-
cluded in the differential diagnosis of the urea cycle defect
include: N-Acetylglutamate synthetase (NAGS), carbamyl
phosphate synthetase (CPS), ornithine transcarbamylase
(OTC), argininosuccinic acidemia (AS), and argininosuc-
cinic lyase deficieny (AL) deficiencies.46 NAGS, CPS, AS,
and AL are autosomal recessive. OTC is X-linked. Clini-
cally, the presentations in the neonatal period are virtually
identical due to the hyperammonemia, which is the com-
mon variable. The laboratory evaluation will include the
quanitative analysis of plasma amino acid and urine or-
ganic acids/urine orotic acid analyses.26,49,50 The labora-
tory results will determine the compounds within the urea
cycle that are increased and decreased. This is based on the
detoxification of ammonia as a five-step process (Fig 4).51
It begins with the formation of carbamyl phosphate from
ammonia by carbamyl phosphate synthetase. Carbamyl
phosphate is added to ornithine to form citrulline by orni-
thine transcarbamylase. Citrulline is converted to argini-
nosuccinate by argininosuccinate synthetase, which is then
cleaved to produce arginine by argininosuccinate lyase.
Arginine is cleaved by arginase to form urea and ornithine.
The urea is excreted in the urine. The ornithine is now
available to restart the cycle again.
The plasma citrulline and argininosuccinate provide the
distinguishing features among the urea cycle defects. If
citrulline is absent or decreased, urine orotic acid will
differentiate between NAGS, CPS, and OTC deficiency. In
NAGS and CPS, the urine orotic acid will be low; while in
OTC it is elevated.52,53 After OTC, CPS and NAGS have
been excluded and, if the citrulline level is normal, the
disorder to consider is hyperornithinemia–hyperammone-
mia–homocitrullinuria (HHH) syndrome.54 If the citrul-
line level is elevated, the agrininosuccinic acid level will
aid in the diagnosis between AL, also known as arginino-
succinic aciduria and AS, also known as citrullinemia. In
citrullinemia, argininosuccinic acid is deficient.55 Thus,
citrulline is produced in massive quantities. In AS, there
will be a moderate increase in citrulline with increased
levels of argininosuccinic acid and its anhydrides.56 A
defect in the last step in the urea cycle, arginase, does not
usually present in the neonatal period, but increasing
Table 5. Errors of Metabolism with Hyperammonemia
in Newborns
Amino acids defects
Argininosuccinic acid lyase deficiency (AL)
Argininosuccininc acid synthetase deficiency (AS)
Carbamyl phosphate synthetase deficiency (CPS)
Hyperornithinemia–hyperammonemia–homocitrullinemia
syndrome (HHH)
Lysinuric protein intolerance (LPI)
Ornithine transcarbamylase deficiency (OTC)
N-Acetylglutamate synthetase deficiency (NAGS)
Fatty acid oxidation defects
Carnitine acylcarnitine translocase deficiency (CACT)
Carnitine palmitoyltransferase II deficiency (CPT-II)
Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency
(LCHADD)
Very long chain acyl-CoA dehydrogenase deficiency
(VLCADD)
Organic acidemia defects
3-Hydroxy-3-methylglutaryl-CoA (HMG) lyase deficiency
Isovaleric acidemia (IVA)
Methylmalonic acidemia (MMA)
Multiple acyl-CoA dehydrogenase deficiency (MADD)
Propionic acidemia (PA)
Table 4. Odors Associated with Errors
of Metabolism
Odor Disorder
Acid like Methylmalonic acidemia (MMA)
Cabbage like Tyrosinemia, type 1
Methionine malabsorption
Cat urine 3-Methylcrontonylglycinuria
(MCC)
Multiple carboxylase deficiency
(MCD)
Curry Maple syrup disease (MSD)
Fish market Trimethylaminuria
Musty, mousy Classical phenylketonuria (PKU)
Maple syrup or burnt
sugar
Maple syrup disease (MSD)
Rancid butter Tyrosinemia, type 1
Sulphurous like Cystinuria
Sweaty feet Isovaleric acidemia (IVA)
Multiple acyl-CoA dehydrogenase
deficiency (MADD or glutaric
acidemia, type II, GAII)
Note: Adapted with permission from Blau N, Blaskovics et al:
Simple tests in urine and blood in Blau N, Duran M, Blaskovics
ME, Gibson KM (eds.): Physician’s Guide to the Laboratory
Diagnosis of Metabolic Diseases (ed 2). Berlin, Springer, 2003;
pp 3-10.
knowledge of this disorder and use of tandem mass spec-
trometry may result in earlier diagnosis during the neona-
tal period.57-59
Neonates with profound and prolonged hyperammone-
mia with coma due to urea cycle defect will have had a
neurological insult to the brain that may be significant. If
so, the option of withdrawal of support rather than aggres-
sive intervention should be discussed with the parents.60
During the acute phase of treatment of a newborn with
a urea cycle defect, the therapy is multifocused. Initial
treatment at this time is directed toward the removal of the
accumulating metabolites, such as ammonia. Intravenous
glucose is administered to restore hydration, as the major-
ity of the newborns with urea cycle defect are dehydrated
as a consequence of poor oral intake and vomiting. With
hydration, tissue perfusion is increased, which protects
renal function and blunts further catabolic production of
nitrogen. The preferred choice of fluids is 10% dextrose
with salts until definitive therapy is available.60 All dietary
protein may be discontinued for 24 hours to decrease the
Fig 3. Simplified flowchart for evaluation of hyperammonemia in the newborn. CSPD, carbamyl phosphate synthetase deficiency; HHH,
hyperornithinemia–hyperammonemia–homocitrullinuria syndrome; IVA, isovalemic acidemia; LCHADD, long chain 3-chydroxy-
acyl-CoA dehydrogenase deficiency; MCADD, medium chain acyl-CoA dehydrogenase deficiency; MMA, methylmalonic acidemia;
NAGS, N-acetylglutamate synthetase deficiency; OTC, ornithine transcarbamylase deficiency; PCD, pyruvate carboxylase deficiency;
PA, propionic acidemia; THAN, transient hyperammonemia of the newborn; VLCADD, very long chain acyl-CoA dehydrogenase
deficiency. Adapted with permission from Hudak ML, Jones MD, Brusilow SW. Differentiation of transient hyperammonemia of the
newborn and urea cycle enzyme defects by clinical presentation. J Pediatr 107:712-719, 1985.
protein load.60 Caloric intake is provided as carbohydrate
and fat. During this period, hemodialysis most often is
needed.29 As with a newborn with an organic acidemia, if
the hospital is unable to offer hemodialysis, transfer of the
newborn to another medical center with hemodialysis ca-
pability should be strongly considered. Exchange transfu-
sions, peritoneal dialysis, or hemofiltration are less effi-
cient than hemodialysis in managing these disorders.30
Drug therapy is administered to provide an alternative path
for nitrogen excretion. Intravenous sodium phenylacetate
combines with glutamine to produce phenylacetylglu-
tamine, which is excreted in the urine.61,62 Sodium benzo-
ate combines with glycine to produce hippurate. Hippurate
is rapidly cleared by the kidneys.63,64 With the removal of
the excessive nitrogen, there is a decrease in arginine
synthesis. As a result, arginine becomes an essential amino
acid that must be replaced.65-67 The assistance of a dieti-
cian with experience with EM is essential. The diet in-
volves protein restriction for life to an amount tolerated
without causing hyperammonemia and preventing exces-
sive protein catabolism while at the same time providing
the body with the nutritional needs for growth and devel-
opment.68,69
The overall prognosis for newborns with a urea cycle
defect is guarded. Without treatment, these newborns will
die. Even with aggressive medical intervention, many will
die. Those newborns that do survive may have neurolog-
ical insult and recurrent life-threatening metabolic crises.
The long-term outcome into adulthood is largely un-
known, as the oldest children are just surviving past child-
hood. Many of the children eventually die and have de-
velopmental delays in physical growth and cognitive
skills.70-72 The long-term correction of a urea cycle defect
is the correction of the enzymatic defect within the hepa-
tocytes. Liver transplantation has been successful in in-
fants with CPS and OTC.73-75 After transplantation, the
serum ammonia levels fall to normal levels without the
need for protein restriction or medications. With advances
in liver transplantation, the indications for liver transplan-
tation for urea cycle defects are changing.76,77 Because of
the limited number of livers available for transplantation,
gene therapy could provide the ultimate correction of the
urea cycle defect. This area of laboratory and clinical
research has the potential to reduce the morbidity and
mortality seen in urea cycle defects.78-83
Fig 4. Simplified schematic of urea cycle with enzyme defects.
Evaluation of the Severely Ill Neonate
Near Death
In some situations, such as severe early onset, late-diagnosed OTC, survival of the newborn may be im-
possible. In most neonatal intensive care units, there is
protocol for dealing with a dying newborn. However, there
are several steps that must be taken to increase the prob-
ability of a specific diagnosis postmortem, when an EM is
suspected.84-86 The collection of blood, urine, and cerebro-
spinal fluid is outlined in Table 6. Many of these samples
may be collected before death. Parental permission for
skin biopsy and autopsy must be requested and obtained.
A full- thickness skin sample by 3 to 4 mm punch biopsy
should be obtained, placed in tissue culture medium, kept
at room temperature, and sent within 24 hours to the
appropriate laboratory where the fibroblasts can be grown
in culture. A skin biopsy is optimal if it can be done before
death. A discussion with the parents regarding an autopsy
for the purpose of investigation of a suspected EM needs
to occur if possible before the newborn’s death. Ideally,
the autopsy should be performed less than 4 hours after
death before postmortem changes can compromise the
integrity of the enzyme system. At autopsy, samples of
liver, spleen, muscle, heart, kidney, and brain should be
obtained and stored in liquid nitrogen or at –70°C. Also
readily available at autopsy, bile should be collected and
frozen. A small amount of bile should be spotted on
newborn filter paper to be used in the postmortem assay of
acylcarnitines.87 If there is a lack of urine, postmortem
vitreous humor from the eye is easily collected by aspira-
tion and subsequently frozen for electrolyte and organic
acid-analysis.89 Before shipment to laboratories, the labo-
ratories should be notified of the precious samples that are
being shipped to facilitate proper processing, storing, and
analysis. These specimens are vital to provide resolution to
the family for the cause of death. Parents need to be
counseled regarding the recurrence risk for most of these
disorders. In addition, they need to be made aware that,
without a specific diagnosis, future prenatal diagnosis is
impossible.
Summary
The ability to diagnose more and more EM during theneonatal period is due to advances in biochemical
genetics. After initial laboratory studies, certain condi-
tions, such as metabolic acidosis and hyperammonemia,
will be key clues to signal the need for further consultation
with a metabolic disease specialist and more specific lab-
oratory studies, though absence of these derangements
does not preclude an EM diagnosis. Initial therapy is
directed toward stabilization of the neonate. Long- term
care is dependent and based on a definitive EM diagnosis.
The majority of therapies are lifelong and require contin-
ual nutritional, medical, and laboratory monitoring. As
children with EM are now surviving long term, the ability
to provide them and their families anticipatory guidance as
to their long-term physical, mental, and emotional needs is
becoming increasingly important. As these children reach
adulthood, their reproductive abilities and the teratogenic
effect that their disease or its treatment can or will have on
their children is unknown. In virtually all cases of probable
EM, the diagnosis is possible even if it is established
postmortem. A diagnosis is essential to provide the family,
Table 6. Collection of Blood, Urine, and Cerebrospinal Fluid for Metabolic Evaluation in the Dying Newborn
Blood
Amino acids 1 ml in EDTA or heparin tube
Ammonia 1 ml in lithium heparin tube on ice
Blood gas 0.3 ml in heparin-coated syringe
Carnitine (free and total) 1 ml in lithium heparin tube on ice
Comprehensive metabolic panel 0.5 ml in lithium heparin tube
Fatty acid profile 0.3 ml in fluoride heparin tube
Hematology 0.5 ml in EDTA tube (no capillary)
Lactic acid 0.6 ml in 0.6 ml sodium fluoride tube on ice
Urine
ph, ketone bodies, reducing substances, amino acids, organic acids 5 ml, freeze at 20°C
Cerebrospinal fluid
Amino acids 0.5 ml in plastic tube
Cells, protein, glucose 0.5 ml in plastic tube
Culture 0.5 ml in sterile plastic tube
Lactic acid 0.5 ml in plastic tube
Note: Adapted with permission from Oregon Health and Science University Laboratory Services Manual, 2003.
who may have already suffered the loss of a newborn, with
thoughtful genetic counseling.
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